Skip to main content

Table 3 Treatment modifications and selected adverse events under therapy

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

  HIV-negative   HIV-positive  
   No HAART NRTI-containing NRTI-free
  Arm A Arm B Arm C1 Arm C2
  n = 50 n = 49 n = 49 n = 20
Elevations serum ALT [%]
    Grade 1/2** 64 61 78 90
    Grade 3/4 - 10 6 5
Anemia [%]     
    Grade 1/2** 10 2 22 5
    Grade 3/4 - - - -
    Maximum Hb loss [g/dl] 3.1 (1.1 - 5.1) 3.0 (0.6 - 5.3) 2.9 (0.8 - 5.7) 3.3 (0.8 - 4.4)
Leucopenia [%]
    Grade 1/2** 40 25 69 55
    Grade 3/4* 0 4 12 10
Thrombocytopenia [%]
    Grade 1/2 44 35 51 55
    Grade 3/4 4 - 10 5
Clinical adverse events [%]
    Grade 1/2 70 63 63 90
    Grade 3/4 12 18 8 5
Dose reduction PegIFN [%]†* 22 8 14 5
    % of total dose received 84 87 81 88
Dose reduction RBV [%]† 28 8 25 15
    % of total dose received 86 81 79 90
Treatment discont. AEs [%] 8 18 8 10
  1. * Statistically significant difference comparing arm A with arms B and C (HIV-positive vs. HIV-negative)
  2. ** Statistically significant difference comparing arm B versus C1 versus C2
  3. †Percent of patients who were dose reduced for pegylated interferon (PegIFN) or ribavirin (RBV) and respective percent of the cumulative dose received.
  4. Data shown as percent of patients or median (95% range)
  5. NRTI nucleos(t)ide reverse transcriptase inhibitor, ALT serum alanine aminotransferase, Treatment discont. AEs Treatment discontinuation due to adverse events.